Back to search
FDAFDA · Food and drugs·Recall number D-0151-2026

Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.

Published November 12, 2025 · Recall initiated: October 13, 2025

Summary

FDA records drug Class II recall D-0151-2026, published November 12, 2025 and initiated October 13, 2025. Recalling firm: Teva Pharmaceuticals USA, Inc; Status: Ongoing; Reported quantity: 4680 cartons; Lot: Lot # 100062316, Exp Date: 01/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent drug; Clavulanate Potassium component

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA, Inc
Distributor
Distributed in three (3) States: MS, OH, CA.
Lot
Lot # 100062316, Exp Date: 01/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7. recalled?

Yes. FDA published recall D-0151-2026 on November 12, 2025. Reported hazard: Subpotent drug; Clavulanate Potassium component

What should I do if I have this product?

Voluntary: Firm initiated · Letter